Respiratory syncytial virus disease burden in adults aged 60 years and older in high‐income countries: A systematic literature review and meta‐analysis-Reference-Cited by-同舟云学术

Respiratory syncytial virus disease burden in adults aged 60 years and older in high‐income countries: A systematic literature review and meta‐analysis

Published:2022-11-11 Issue:1 Volume:17 Page:
ISSN:1750-2640
Container-title:Influenza and Other Respiratory Viruses
language:en
Short-container-title:Influenza Resp Viruses

Author:

Savic Miloje¹,Penders Yolanda¹^ORCID,Shi Ting²,Branche Angela³^ORCID,Pirçon Jean‐Yves¹

Affiliation:

1. GSK Wavre Belgium

2. Usher Institute University of Edinburgh Edinburgh UK

3. Division of Infectious Diseases, Department of Medicine University of Rochester Rochester New York USA

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.13031

Reference51 articles.

1. Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults

2. DevadigaR EckermannT HelmanLL et al.Respiratory syncytial virus (RSV)‐associated burden of disease in older adults in Europe and the United States. Abstract E&E‐23. Presented at the 6th ReSViNET Conference 2021 [online virtual];https://www.resvinet.org/uploads/2/2/2/7/22271200/abstract_booklet_rsvvw21.pdf. Accessed 27 February 2022.

3. Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study;Vaccine;2024-12

2. Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trial;Respiratory Investigation;2024-11

3. Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study;The Lancet Infectious Diseases;2024-09

4. The long-term efficacy of a respiratory syncytial virus vaccine for older adults;The Lancet Infectious Diseases;2024-09

5. Burden of respiratory syncytial virus infections in older adults with acute respiratory infection in Japan: An epidemiological study among outpatients;Respiratory Investigation;2024-09